Results 191 to 200 of about 99,302 (260)
Improving access to direct acting antivirals via a multimodal integrated care program in an addiction medicine clinic
The American Journal on Addictions, EarlyView.Abstract Background and Objectives
Injection drug use is a driver of hepatitis C virus (HCV) transmission, thus integrating HCV care into addiction care is likely necessary for HCV elimination. Here we describe how we integrated HCV care into our addiction medicine (AM) clinic and evaluate its effect on HCV treatment.Arya Zandvakili, Joseph Rattenni, James Burton, Lakshmi Guduguntla, Marcus Osman, Sayeh Sabbagh, Stephan Arndt, Ben Miskle, Quanhathai Kaewpoowat, Michael Ohl, Andrea Weber, Alison Lynch +11 morewiley +1 more sourceFel d 1‐Expressing Plant‐Derived Bioparticle: A Novel Treatment for Cat Allergy
Allergy, EarlyView.This study investigates the allergenicity and immunogenicity profile of a novel plant‐derived Fel d 1 bioparticle (eBP). Fel d 1 eBP promotes immune tolerance by redirecting allergic Th2 responses toward Th1 and IL‐10–producing regulatory pathways, including Bregs.Janice A. Layhadi, Liliana Cifuentes Gutierrez, Sean T. Keane, William Fulton, Nichell A. Samson, Lily Y. D. Wu, Paulina Filipaviciute, Prista Hikmawati, Oleksandra Fedina, Ana Jimenez‐Gil, Stephen R. Durham, Guy Scadding, Guy Tropper, Louis‐Philippe Vézina, Patrick Colin, Ronald van Ree, Mohamed H. Shamji +16 morewiley +1 more sourceA Case for Anti‐IgE Vaccination
Allergy, EarlyView.ABSTRACT
Immunoglobulin E (IgE) plays a central role in allergic diseases by binding to the high‐affinity receptor FcεRI on mast cells and basophils, where allergen‐induced crosslinking triggers potent inflammatory responses. Various mechanisms by which IgE responses are generated and functionally regulated remain elusive despite many years of research.Paul Engeroff, Zahra Gharailoo, Monique Vogel, Martin F. Bachmann +3 morewiley +1 more sourceA Personalised Vaccination Program Based on Immune Reconstitution in Paediatric Cancer Survivors
Acta Paediatrica, EarlyView.ABSTRACT Aims
Paediatric cancer survivors often experience treatment‐induced immunosuppression, requiring post‐treatment revaccination. However, immune recovery timelines vary, and current revaccination guidelines, largely based on data of varied quality derived from studies on acute‐lymphoblastic‐leukaemia (ALL), may not be applicable across all ...Menucha Jurkowicz, Raz Somech, Dan Dominissini, Nathan Keller, Efrat Dresner, Michal Paret, Gilad Sherman, Guy Katzenellenbogen, Elina Gelman, Keren Asraf, Ram Doolman, Atar Lev, Amos J. Simon, Helly Vernitsky, Assaf Barg, Hana Golan, Amos Toren, Michal Stein +17 morewiley +1 more sourceDiagnostic Impact of Liver Biopsy Among Antinuclear Antibody Positive Individuals With Mild Liver Enzyme Elevation
Alimentary Pharmacology &Therapeutics, EarlyView.In ANA‐positive patients with suspected autoimmune hepatitis (AIH), liver biopsy rarely altered therapeutic management when alanine aminotransferase (ALT) was below 101 U/L and cirrhosis was absent. These findings suggest that biopsy may be safely deferred in this low‐risk group.David Mehdi Asgher Niazi, Alphonse Charbel, Jan Pfeiffenberger, Uta Merle, Jessica Seessle, Theresa Wenz, Christa Flechtenmacher, Patrick Michl, Conrad Rauber +8 morewiley +1 more sourceA Nationwide Assessment of Anticholestatic Therapy Uptake in Patients With Primary Biliary Cholangitis: Opportunities for Optimisation
Alimentary Pharmacology &Therapeutics, EarlyView.Among a nationwide population with primary biliary cholangitis, almost all people were prescribed ursodeoxycholic acid (UDCA). However, UDCA was insufficiently dosed in a one third of them. The results indicate that first‐line treatment can be optimized, particularly in those with a biochemical response and higher body weight.Ellen Werner, Maria C. B. van Hooff, Gemma H. X. Weijsters, Maria A. van de Vrie, Rozanne C. de Veer, Ulrich Beuers, Joost P. H. Drenth, Frans J. C. Cuperus, Remco van Dijk, Bart J. Veldt, Michael Klemt‐Kropp, Suzanne van Meer, Robert C. Verdonk, Hajo J. Flink, Jan Maarten Vrolijk, Matthijs Kramer, Cyriel Y. Ponsioen, Kirsten Boonstra, Femke Boersma, Hendrik J. M. de Jonge, Frank H. J. Wolfhagen, L. C. Baak, Susanne L. Onderwater, Jeroen D. van Bergeijk, Paul G. van Putten, Gijs J. de Bruin, Rob P. R. Adang, Maria N. Aparicio‐Pages, Wink de Boer, Frank ter Borg, Hanneke van Soest, Elsemieke S. de Vries, Nicole S. Erler, Bettina E. Hansen, Harry L. A. Janssen, Adriaan J. van der Meer, on behalf of the Dutch PBC Study Group, Adriaan J. van der Meer, Anne Vrieze, A. (Sander) van der Beek, Bart J. Veldt, Bart van Hoek, Bettina E. Hansen, Cyriel Y. Ponsioen, Daphne M. Hotho, Djuna L. Cahen, Edith M.M. Kuiper, Ellen Werner, Elsemieke de Vries, Femke Boersma, Frank C. Bekkering, Frank H.J. Wolfhagen, Frank ter Borg, Frans J.C. Cuperus, Gemma X. Weijsters, Gijs J. de Bruin, Hajo J. Flink, Hanneke van Soest, Hans H.K. Thio, Harry L.A. Janssen, Hendrik J.M. de Jonge, Huseyin Aktas, Ingrid C.A.W. Konings, J. Marleen de Vree, J. (Netty) van Kemenade, Jan Maarten Vrolijk, Janne E. van Rooij, Jeroen D. van Bergeijk, Jerome Sint Nicolaas, Johan P.H. Kuyvenhoven, Johannes Schmidt‐Böhmer, Joost P.H. Drenth, Khalida Soufidi, Kirsten Boonstra, Laurens A. van der Waaij, L. (Bert) C. Baak, Leendert H. Oterdoom, Lisette J.H. van Dam, Ludger S.M. Epping, Paul J. Bus, Maaike J. Denters, Marcel Cazemier, Maria C. van Hooff, Maria N. Aparicio‐Pages, Marjo J. Kerbert‐Dreteler, Martijn J. ter Borg, Martine A.M.C. Baven‐Pronk, Matthias C. Jurgens, Matthijs Kramer, Menno Beukema, Merel M. Tielemans, Michael Klemt‐Kropp, Nicole F.M. van Gerven, Nicole S. Erler, Paul G. van Putten, Philip W. Friederich, Pieter C.J. ter Borg, Robert C. Verdonk, Remco van Dijk, Rob P.R. Adang, Robert Roomer, Rozanne C. de Veer, Sander de Kort, Sigrid Vandebosch, Stephan H.C. van Stiphout, Stephan Schmittgens, Sunje Abraham, Susanne L. Onderwater, Suzanne van Meer, Sven J. van den Hazel, Tiki D. Blom, Tim C.M.A. Schreuder, Tom J.G. Gevers, Ulrich Beuers, Ulrike de Wit, Wink de Boer, Yasser A. Alderlieste +116 morewiley +1 more sourceClinical features and comorbidity patterns in early and very early rheumatoid arthritis: Insights from a China nationwide survey
Rheumatology &Autoimmunity, EarlyView.Haojie Xu, Liyun Zhang, Yuehong Huo, Rui Wu, Lijun Wu, Ling Lei, Linyu Geng, Chunyu Tan, Xiaomei Li, Ru Li, Yin Su, the Women's Rheumatoid Arthritis Research Collaborative Group +11 morewiley +1 more sourceCorrelation of Bile Acid Dynamics to Bulevirtide Response and Disease Severity in Patients With Hepatitis D
Alimentary Pharmacology &Therapeutics, EarlyView.Bulevirtide increases bile acid levels in most patients; however, changes in bile acids do not predict virological response or adverse events, nor do they reflect treatment adherence. After discontinuation of bulevirtide, bile acid levels rapidly decline.Marlene Hintersteininger, Michael Schwarz, Philipp Schwabl, Lukas Hartl, Lorenz Balcar, Benedikt Silvester Hofer, Georg Kramer, Christian Sebesta, Paul Thöne, Patrik Attalla, Michael Gschwantler, Michael Trauner, Mattias Mandorfer, Thomas Reiberger, Mathias Jachs +14 morewiley +1 more sourceCheckpoint inhibitors, obinutuzumab plus PET‐adapted ultra‐low dose nodal radiotherapy yield high efficacy in treatment‐naïve follicular lymphoma: Results from the phase II ‘FLUORO’ study
British Journal of Haematology, EarlyView.Summary
Follicular lymphoma (FL) first‐line chemoimmunotherapy yields high efficacy but serious toxicity in 65% of patients. In high tumour burden treatment‐naïve FL, we aimed to exploit known immunostimulatory and cytotoxic properties of combination checkpoint inhibition (atezolizumab) and obinutuzumab (6 cycles) with positron emission tomography (PET)Arina Martynchyk, Geoffrey Chong, Richard Khor, Denise Lee, Sze Ting Lee, Andrew M. Scott, Anneke C. Grobler, Belinda A. Campbell, Thanuja Thachil, Kate Manos, Genevieve Douglas, Alexandra Romano, Jodie B. Palmer, Melinda Burgess, Colm Keane, Eliza A. Hawkes +15 morewiley +1 more source
